CoChat
Sign Up
Cited by 65

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence

Tousi, Babak·2015·Neuropsychiatric Disease and Treatment
DOI 10.2147/ndt.s61309PMC PMC4327563
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s61309

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 20

  1. [3]Counts SE Lahiri DK Overview of immunotherapy in Alzheimer’s disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD Curr Alzheimer Res 2014 11 7 623 625 25156573 PMC5870835
  2. [4]Boada M Ortiz P Anaya F Hernández I Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization Drug News Perspect 2009 22 6 325 339 19771322
  3. [5]Raber J Huang Y Ashford JW ApoE genotype accounts for the vast majority of AD risk and AD pathology Neurobiol Aging 2004 25 5 641 650 15172743
  4. [6]Kim WS Weickert CS Garner B Role of ATP-binding cassette transporters in brain lipid transport and neurological disease J Neurochem 2008 104 5 1145 1166 17973979
  5. [7]Chawla A Boisvert WA Lee CH A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis Mol Cell 2001 7 1 161 171 11172721
  6. [8]Liang Y Lin S Beyer TP A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes J Neurochem 2004 88 3 623 634 14720212
  7. [9]Laffitte BA Repa JJ Joseph SB LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes Proc Natl Acad Sci U S A 2001 98 2 507 512 11149950 PMC14617
  8. [14]Veeraraghavalu K Zhang C Miller S Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models” Science 2013 340 6135 924-f 23704555
  9. [15]Landreth GE Cramer PE Lakner MM Response to comments on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models” Science 2013 340 6135 924-g 23704556 PMC3714602
  10. [16]LaClair KD Manaye KF Lee DL Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice Mol Neurodegener 2013 8 1 18 23764200 PMC3693923
  11. [17]Boehm-Cagan A Michaelson DM Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene J Neurosci 2014 34 21 7293 7301 24849361 PMC6608187
  12. [18]Tai LM Koster KP Luo J Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo J Biol Chem 2014 289 44 30538 30555 25217640 PMC4215234
  13. [19]Strittmatter WJ Saunders AM Goedert M Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease Proc Natl Acad Sci U S A 1994 91 23 11183 11186 7972031 PMC45191
  14. [20]Harris FM Brecht WJ Xu Q Mahley RW Huang Y Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc J Biol Chem 2004 279 43 44795 44801 15322121
  15. [21]Gniadecki R Assaf C Bagot M The optimal use of bexarotene in cutaneous T-cell lymphoma Br J Dermatol 2007 157 3 433 440 17553039
  16. [22]Sherman SI Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma Clin Lymphoma 2003 3 4 249 252 12672276
  17. [24]Duvic M Martin AG Kim Y Worldwide Bexarotene Study Group Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 2001 137 5 581 593 11346336
  18. [25]Musolino A Panebianco M Zendri E Santini M Di Nuzzo S Ardizzoni A Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: the role of omega-3 fatty acids Br J Haematol 2009 145 1 84 86 19208096
  19. [31]Fantini J Di Scala C Yahi N Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer’s β-amyloid peptides ACS Chem Neurosci 2014 5 3 216 224 24383913 PMC4058752
  20. [32]Bomben V Holth J Reed J Cramer P Landreth G Noebels J Bexarotene reduces network excitability in models of Alzheimer’s disease and epilepsy Neurobiol Aging 2014 35 9 2091 2095 24767949 PMC4053509

Cited by

Sorted by citations

Metadata

Authors
Tousi, B.
Venue
Neuropsychiatric Disease and Treatment
Publisher
Informa UK Limited
Published
2015-02
Pages
311
ISSN
1178-2021
DOI
10.2147/ndt.s61309
PMC
PMC4327563
Cited by
65
References
7
Language
en
Licence
creativecommons.org/licenses/by-nc/3.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review